Clinical Trial SuccessArbutus reported further follow-up data showing six patients in the A1 and A2 cohorts reached undetectable levels of HBsAg and achieved seroconversion, a significant milestone in hepatitis B treatment.
Financial StabilityThe company believes its current cash position is sufficient to fund operations into the fourth quarter of 2026, indicating strong financial stability.
Litigation UpdatesPositive litigation updates and Arbutus' commitment to not use its ATM have driven stock outperformance.